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journal.publications.chestneHepatopulmonary syndrome (HPS) is a liver-induced lung disorder deﬁned as a triad of liver
disease, pulmonary vascular dilatation, and a defect in oxygenation. It can complicate chronic
liver disease of any etiology, but is most commonly associated with portal hypertension. Severe
liver disease with portal hypertension is present in 2% to 8% of patients with cystic ﬁbrosis
(CF), but to date, to our knowledge, only one patient with CF has been reported to suffer from
HPS. Here, we describe two patients with CF diagnosed with HPS, one subsequent to unresolved
hypoxemia and the other following screening for HPS performed in our center. We speculate
that HPS is underdiagnosed in patients with CF because of their coexisting respiratory
morbidity, and we advocate routine screening for every patient with CF who has liver disease
and portal hypertension. CHEST 2016; 149(2):e35–e38
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is considered a major cause of morbidity and
is the third-leading cause of mortality after
pulmonary disease and transplantation
complications in patients with cystic ﬁbrosis
(CF).1-3 The prevalence of CFLD is not well
established and ranges from 2% to 68%.3,4
Clinical presentation may include mildly
elevated liver enzyme levels in anasymptomatic
patient, hepatic steatosis, focal biliary cirrhosis,
and multilobular biliary cirrhosis with
accompanying portal hypertension,2,4,5 which
occurs in 2% to 8% of the patients.3,6,7
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t.orgoxygenation, and intrapulmonary vascular
abnormalities, referred to as intrapulmonary
vascular dilatations.8-10 The estimated
prevalence of HPS among patients with
non-CF chronic liver disease, based on data
from liver transplant centers, ranges between
5% and 32%.11 To our knowledge, only one
case report of HPS in a patient with CF12 is
available in the literature. Since HPS is
characterized by hypoxemia, and patients
with CF often suffer hypoxia because of their
lung disease, it is likely that in these patients,
HPS might be underdiagnosed. Still, the
unique hemodynamic-gas exchange pattern
of HPS enables it to be distinguished from
cardiopulmonary disorders.13 Here, we reportENCE TO: David Shoseyov, MD, Pediatric Pulmonology
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two cases of HPS that were diagnosed in our CF center
and present the screening tests required for evaluation
of HPS in patients with CF and current treatment.
Case Reports
Case 1
A 16-year-old male patient received a diagnosis of CF
at the age of 4 months (genotype DF508/G542X).
His CFLD was ﬁrst detected at the age of 3 years because
of elevated liver transaminase levels and subsequent
progressive portal hypertension. He developed
esophageal varices, which were ﬁrst ligated at the age
of 7 years. At age 14 years, he developed hypoxemia
that gradually progressed within 6 months, with a
decrease in arterial oxygen saturation (Sao2) at room
air of 95% to 83%. At that time, his lung disease was
stable, with a FEV1 of around 70% predicted and with
no episodes of severe pulmonary exacerbations requiring
hospitalization. His sputum showed growth of chronic
methicillin-resistant Staphylococcus aureus and,TABLE 1 ] Patient Characteristics at Time of Diagnosis of H
Characteristic C
CFTR genotype delF50
Age at diagnosis of CFLD, y
Age at diagnosis of HPS, y
Sex M
FEV1, L (% pred) 2.1
FVC, L (% pred) 2.9
FEV1/FVC, %
TLC % pred
RV/TLC, %
DLCO(Hb), mmol/min/kPa (% pred)
Kco(Hb), mmol/min/kPa/L (% pred)
Room-air Pao2, mm Hg
Room-air Paco2, mm Hg
pH
A-a Po2, mm Hg
Hemoglobin, g/dL
Platelet count, mm3 4
INR
Albumin, g/L
Bilirubin, mg/dL
AST, U/L
ALT, U/L
A-a Po2 ¼ alveolar-arterial Po2 gradient; ALT ¼ alanine transaminase; AST ¼
CFTR ¼ cystic ﬁbrosis transmembrane conductance regulator; DLCO(Hb) ¼ sin
HPS ¼ hepatopulmonary syndrome; INR ¼ international normalized ratio; K
pred ¼ predicted; RV ¼ residual volume; TLC ¼ total lung capacity.
e36 Selected Reportsintermittently, Pseudomonas aeruginosa, as well as
different Aspergillus species. On physical examination,
the patient was cyanotic without apparent dyspnea,
his lungs were clear, and heart sounds were normal;
the spleen was signiﬁcantly enlarged (20 cm) but stable
over the last 3 years. Supplemental oxygen, 1.5 L/min
by nasal cannula, was associated with an increase in Sao2
to 92%. Chest CT scan showed mild progression of
his pulmonary disease with right upper lobe and right
middle lobe bronchiectasis. His serum IgE levels were
normal, whereas speciﬁc IgE levels for Aspergillus
were slightly elevated. Thrombocytopenia secondary
to hypersplenism was stable, liver synthetic function was
mildly impaired but stable (international normalized
ratio ¼ 1.75 s; albumin serum levels within normal
limits). Treatment with oral and inhaled antibiotics
did not improve his FEV1 or Sao2. Additional clinical
characteristics are presented in Table 1.
Arterial blood-gas sample results showed Pao2 of
37.6 mm Hg, and the alveolar-arterial oxygen gradientPS
ase 1 Case 2
8/G542X W1282X/W1282X
3 7
16 17
ale Male
4 (71) 2.91 (91)
4 (83) 4.07 (108)
85 85
ND 144
ND 35
ND 7.70 (92)
ND 1.46 (73)
37.6 72.3
45.2 34.4
7.39 7.44
45 21
15.7 12.4
1,000 28,000
1.75 1.58
34 40
1.9 2.3
57 38
36 32
aspartate transaminase; CFLD ¼ cystic ﬁbrosis-associated liver disease;
gle-breath carbon monoxide diffusing capacity adjusted for hemoglobin;
co(Hb) ¼ DLCO, adjusted for hemoglobin, corrected for alveolar volume;
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(A-a gradient) was elevated (45 mm Hg). A contrast-
enhanced echocardiography (CEE) with agitated
saline injected to a peripheral vein demonstrated a
nonintracardiac right to left shunt, with no evidence of
pulmonary hypertension. This established the diagnosis
of HPS. Platypnea and orthodeoxia, which are clinical
features of HPS, were not assessed in this patient.
According to the marked diminished oxygenation and
the disease severity categorization,9 HPS was staged
as very severe. Subsequently, the patient underwent a
successful liver transplantation. Sao2 improved gradually
to 95% on room air within 2 months after liver
transplantation. Repeated CEE analysis normalized
with no evidence of a shunt, a single-breath carbon
monoxide diffusing capacity was 1.46 mmol/min/kPa/L
(84% predicted), and an annual best FEV1 following the
liver transplant was 91% predicted.
Subsequent to diagnosing HPS in this patient, we decided
to screen for HPS all patients with CF at our center who
had CFLD. Two additional patients were screened by
performing measurements of arterial blood gas and CEE.
Concomitant HPS was diagnosed in one (case 2).
Case 2
A 17-year-old male patient (genotype W1282X/
W1282X) received a diagnosis of CF at the neonatal
period subsequent to the diagnosis of an older sibling.
He developed CFLD at the age of 7 years and had
progressive portal hypertension, splenomegaly, and
persistent thrombocytopenia. His pulmonary disease
was relatively mild with localized bronchiectasis, as
evident in the chest high-resolution CT scan, a FEV1 of
approximately 90% predicted, and intermittent growth
of methicillin-resistant S. aureus and P. aeruginosa in
sputum cultures, with good response to oral antibiotic
treatment. In addition, he had received a diagnosis of
CF-related diabetes mellitus at the age of 13 years, which
was not well controlled. At the time of diagnosis of HPS,
his pulmonary condition was stable (Table 1) and he did
not suffer from platypnea or orthodeoxia. For 6 years
prior to the diagnosis, the patient had not been treated
with IV antibiotics and his Sao2 on room air was
94%. Pao2 measurement from an arterial blood-gas
sample was 72.3 mm Hg, the calculated A–a gradient was
21 mm Hg (Table 1), and a CEE conﬁrmed the diagnosis
of HPS with no evidence of pulmonary hypertension. Due
to his relatively mild pulmonary disease and moderate
HPS, the patient was not considered a candidate for
orthotropic liver transplantation (OLT). Currently, he isjournal.publications.chestnet.orgclosely followed and aggressively treated for his
pulmonary disease and CF-related diabetes mellitus.Discussion
In patients with CF, pulmonary symptoms related to
progressive chronic lung disease are the most frequent
cause of morbidity and mortality. Thus, caretakers of
patients with CF attribute respiratory symptoms and
signs like dyspnea or hypoxemia to the chronic lung
disease and not to a putative undiagnosed liver disease.
We suspect that in patients with CF who have known
CFLD, HPS is much more frequent than currently
reported and that underdiagnosis based on confounding
symptoms due to the coexisting chronic lung disease is
the reason for the rare reported occurrence. At the
Hadassah CF Center in 2013, where over 140 patients
with CF (children and adults) are treated, three patients
were found to have signiﬁcant liver disease, of whom
two had portal hypertension and received a diagnosis of
HPS. HPS can be associated with any form of chronic
liver disease, but is most commonly associated with
portal hypertension.9 In these patients, hypoxemia with
a relatively mild pulmonary disease raised the suspicion
of HPS.
HPS is characterized by progressive hypoxemia with no
identiﬁable respiratory cause. The underlying reason for
HPS is not entirely understood, but it has been suggested
that increased circulating pulmonary vasodilators
secondary to the liver disease create intrapulmonary
vascular dilatations. These cause hypoxemia by the
combination of intrapulmonary shunting, an alveolar-
capillary diffusion limitation, and a ventilation/perfusion
mismatch.9,10 The estimated 5-year survival of patients
diagnosed with HPS is 23%, with worse estimated
survival in patients with a Pao2 < 50 mm Hg. To
date, no drug therapy has been shown to be useful
in treatment of HPS, and supplemental oxygen
administration, though commonly advised, lacks data
regarding its efﬁcacy in long-term management. OLT
has been shown to induce complete resolution of HPS
in > 80% of patients, with an improved posttransplant
5-year survival rate of 76%. Therefore, diagnosis of HPS
in a hypoxemic patient (Pao2 < 60 mm Hg) is currently
considered an indication for OLT with a higher priority
than for patients with other liver disorders.9,10 In
patients with CF, a combined lung and liver transplant
may be considered. However, in view of the mild
pulmonary disease in our patient, with an FEV1 of
70% predicted, this was not indicated. Furthermore,e37
pulmonary disease in patients with HPS usually
improves after OLT.9,10
Due to the high mortality rate of HPS, the European
Respiratory Society task force on pulmonary-hepatic
vascular disorders suggests screening for HPS by
performing measurements of A-a gradient in all patients
with chronic liver disease who report dyspnea or who
are candidates for liver transplantation.10 In patients
in whom an A-a gradient $ 15 mm Hg is found, it is
recommended to perform a CEE or an IV 99mTc-labeled
albumin scan for the diagnosis of HPS.10 CEE is
considered the gold standard for the diagnosis of HPS,10
but a 99mTc-labeled albumin scan may determine the
degree of the shunt, and has been shown to serve as a
prognostic predictor in patients with HPS.14
However, in patients with CF, the characteristic lung
disease may mask the presence of HPS. Furthermore, an
increased A-a gradient is not uncommon in patients
with moderate to severe CF lung disease. Therefore,
respiratory symptoms or A-a gradient measurements are
not useful to detect HPS in patients with CFLD. Clinical
observation of platypnea and orthodeoxia may raise
suspicion in an alert physician and should be routinely
assessed in patients with CFLD, but absence of these
ﬁndings does not rule out HPS. Therefore, we
recommend that in patients with CFLD and portal
hypertension or with CFLD with hypoxemia, a CEE
should be regularly performed for the evaluation of HPS.
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